Company Overview and News
27 of 94 Monthly Paying (MoPay) U.S. dividend stocks were tagged "safer" by showing positive annual returns, and free cash flow yields greater than their dividend yields as of 5/1/18.
AGNCB CLA APLE FN O.PRF O BTBIF FNLIF OPRF ORC PSEC FN.PR.A ARR CJREF CJR.B AGNCP ARR.PRB ARR.PRA AGNC CPTA PBB
26 of 99 Monthly Paying (MoPay) U.S. dividend stocks were tagged "safer" by showing positive annual returns, and free cash flow yields greater than their dividend yields as of 4/3/18.
TAHO AGNCB CLA APLE FN BTBIF FNLIF ORC PSEC SJT FN.PR.A ARR CJREF THO GHIFF CJR.B AGNCP ARR.PRB ARR.PRA AGNC CPTA PBB
By net gain, NRBAY, TSCFY, TPVG, BANX, APAM, APO, HSBC, AINV, BGCP, and TCRD were Financial Services' Top 10 'safer' dividend stocks. They averaged 20.17% in predicted 1yr. net.
AIY BGCP AINV MVC FNLIF APAM HSB FN.PR.A MVCD GLUSF HSBC.PRA MVCB AZIHF PHXXY HSBC HBCYF HCS.PRB TCRX FN BGCA PHXXF AZIHY AIB TCRD BANX HCS TCRZ TSLF OCSI 0005 HSEA HSEB
TORONTO, March 23, 2018 (GLOBE NEWSWIRE) -- Partners Real Estate Investment Trust ("Partners" or the "REIT") (TSX:PAR.UN) is pleased to announce that it has finalized a $21.5 million mortgage at the REIT's Place Desormeaux property in Longueil, Quebec.
FN.PR.A FN PTSRF FNLIF
Earnings season is beginning to slow with only four Canadian Dividend All-Stars scheduled to report earnings this coming week. Of those, there is only one that might announce a raise. Last week did not go according to plan, so let’s take a look where things went wrong.
STLJF ANCUF NWTUF ANCTF FN PBH.DB.D PBH.DB.B PRBZF NWC ATD.A SJ ATD.B FXNC PBH
9h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to TSX:FN / First National Financial on message board site Silicon Investor.